Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU. Of the 114 evaluable patients, 46 received chlorozotocin, 47 received neocarzinostatin, and 21 received MeCCNU. The response rates to these three drugs were 9%, 4%, and 14% respectively. Median survival times were 4.2, 3.4, and 5.8 months respectively. Toxicity was acceptable with all three agents. Chlorozotocin and neocarzinostatin do not appear to offer any improved response rates over MeCCNU for patients with disseminated malignant melanoma.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011897:Random Allocation; D012673:Semustine / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013311:Streptozocin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009353:Zinostatin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D012673:Semustine; C007028:chlorozotocin; D013311:Streptozocin; D009353:Zinostatin